Brian di Donato

Brian Di Donato is an accomplished financial executive with extensive experience across various sectors, including pharmaceuticals, hedge funds, and capital markets. Currently serving as the Chief Financial Officer and Head of Strategy at Immunocore since May 2020, Brian is focused on leveraging T-cells to combat cancer and infectious diseases. Brian holds a position on the Board of Directors at iECURE, inc. and previously acted as CFO at Achillion Pharmaceuticals, overseeing its sale to Alexion Pharmaceuticals for $1.2 billion. Prior roles include Co-Portfolio Manager at Sorin Capital Management, President of Capmark Investments, and various positions in fixed income at Morgan Stanley and UBS Securities. Brian's foundational military experience as an Aerospace Maintenance Duty Officer in the US Navy and an educational background with degrees from NYU Stern School of Business, Penn State Abington, and Villanova University further enhance Brian's diverse expertise in finance and management.